- Policy
- About 70% of new anticancer drugs are listed
- by Lee, Hye-Kyung Jun 11, 2020 06:22am
- The average listed rate for new drugs approved in Korea was 67.2%. Looking at the rate of chemotherapy drug listed alone, it was 70.2%, which is higher than all new drugs. Korea Institute for Health and Social Affairs This data was shown on the 8th through the 'Health and Welfare ISSUE&FOCUS (Silvia Park, Korea Institute for Pharmaceutica
- Company
- HPV vaccine Gardasil9 eligible age to extend up to 45
- by Eo, Yun-Ho Jun 10, 2020 06:12am
- The vaccination eligible age for the human papillomavirus (HPV) vaccine Gardasil9 would be extended in Korea as well. Pharmaceutical industry sources reported, MSD has submitted an indication extension application to Ministry of Food and Drug Safety (MFDS) to vaccinate both female and male in age 27 to 45. The approval may be cleared in
- Company
- Medtronic Korea joined the KDPU
- by An, Kyung-Jin Jun 10, 2020 06:09am
- A union was established in Medtronic Korea, an Irish medical device company. According to the industry on the 9th, Medtronic Korea recently launched an in-house union and joined the new branch of the Korea democratic Pharmaceutical Unions. The union was founded on May 28th. The union sent official letters to the company to formalize the es
- Company
- Labor union protests against Lundbeck Korea for 50 days
- by An, Kyung-Jin Jun 10, 2020 06:09am
- The conflict is deepening between Lunbeck Korea and employees regarding a recent layoff. On June 8, the Lunbeck Korea Chapter of Korea Democratic Pharmaceutical Union protested in front of the company’s head office in Songpa-gu, Seoul. Denouncing the unfair labor practice by the company management, the labor union has been picketing o
- Company
- Accelerating the market entry of JAK inhibitors
- by Kim, Jin-Gu Jun 10, 2020 06:08am
- JAK inhibitors, oral rheumatoid arthritis drugs, are increasing sales in the autoimmune disease treatment market. However, the major item Xeljanz (Tofacitinib) is faltering. For the first time, quarterly sales fell. It is an analysis that the growth of Olumiant(Baricitinib) had an effect. In addition, generics such as Smyraf (Peficitin
- Company
- Rinvoq was approved in Korea
- by Eo, Yun-Ho Jun 9, 2020 06:28am
- Domestic market competition among JAK inhibitors is fierce. According to the related industry, Pfizer's Xeljanz (Tofacitinib), Lilly's Olumiant (Baricitinib), Astellas' Smyraf(Peficitinib) and Abbvie’s Rinvoq (Upadacitinib) were approved on the 4th. Rinvoq's permission is based on five phase III SELECT clinical trials (SELECT-NEXT, SEL
- Policy
- Kolmar begins patent challenge
- by Lee, Tak-Sun Jun 9, 2020 06:28am
- More and more domestic pharmaceutical companies are greedy with generic drugs from Novartis' DPP-4 diabetes treatment drug 'Galvus'. On the 5th, Kolmar Korea filed a passive trial to confirm the scope of a patent right to avoid patents. It has been 7 months since it was approved for bioequivalence test for development of generics in Novemb
- Policy
- Tightening electronic review on antiinfectives from October
- by Lee, Hye-Kyung Jun 9, 2020 06:28am
- Korea’s Health Insurance Review and Assessment Service (HIRA) is tightening the electronic review system regarding the antiinfectives for systemic use. The list of electronic review subjects include AbbVie Korea’s Mavyret, Gilead Science Korea’s Biktarvy, Ildong Pharmaceutical’s Besivo and many other chronic hepatitis type B and C t
- Company
- Will COVID-19 Vaccine be specially imported?
- by Kim, Jin-Gu Jun 9, 2020 06:26am
- The government is reviewing the vaccine being developed by AstraZeneca as a special import for COVID-19. Although it is still in the development stage, it is said that the government and the company had contacted with the plan to urgently introduce it in the form of special import if the clinical trial succeeds. According to the pharmaceutic
- Opinion
- [Reporter’s View] Not penalty but incentive to generics
- by Lee, Tak-Sun Jun 9, 2020 06:26am
- Under the grandeur name of ‘strengthening market competitiveness,’ Korean-made generics are to face various changes in policy in the future. Concerned of excessive number of generics weakening the market competitiveness, the Korean government has already attempted to restrict joint bioequivalence test and reduce pricing of generics with co
